| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802137 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(6 months from now) | |
| US9827317 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(6 months from now) | |
| US7718189 | INSMED INC | Sustained release of antiinfectives |
Jun, 2025
(1 year, 8 months from now) | |
| US8632804 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(3 years from now) | |
| US8679532 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(3 years from now) | |
| US8642075 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Dec, 2026
(3 years from now) | |
| US8226975 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Aug, 2028
(4 years from now) | |
| US9566234 | INSMED INC | Systems for treating pulmonary infections |
Jan, 2034
(10 years from now) | |
| US10251900 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US10751355 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US9895385 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
| US11446318 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(11 years from now) | |
Arikayce Kit is owned by Insmed Inc.
Arikayce Kit contains Amikacin Sulfate.
Arikayce Kit has a total of 12 drug patents out of which 0 drug patents have expired.
Arikayce Kit was authorised for market use on 28 September, 2018.
Arikayce Kit is available in suspension, liposomal;inhalation dosage forms.
Arikayce Kit can be used as treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen, treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen, treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen, treating mycobacterium avium complex (mac) lung disease in adults with cystic fibrosis as part of a combination drug regimen.
The generics of Arikayce Kit are possible to be released after 15 May, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination anti...
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic